DYN · Dyne Therapeutics, Inc.
$24.44
+1.05% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-8.8
Dividend yield
—
Beta
1.06
Avg volume
2M
Employees
0K
2D change
—
5D change
7.28%
10D change
7.96%
30D change
22.40%
60D change
32.59%
MTD change
17.62%
YTD change
31.03%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DYN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-23
Latest call per bank · past 12 months
Morgan Stanley
Overweight$47.00
+92.3% vs priceJP Morgan
Neutral$16.00
-34.5% vs priceRBC Capital
Outperform$30.00
+22.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-23 | Cantor Fitzgerald | Initiates | Overweight | $0.00 |
| 2026-06-26 | TD Cowen | Initiates | Buy | $0.00 |
| 2026-05-15 | Evercore ISI Group | Maintains | Outperform | $34.00 → $33.00 |
| 2026-05-13 | Bernstein | Maintains | Market Perform | $23.00 → $24.00 |
| 2026-03-09 | Chardan Capital | Maintains | Buy | $38.00 |
| 2026-03-03 | Morgan Stanley | Maintains | Overweight | $50.00 → $47.00 |
| 2026-03-03 | Chardan Capital | Maintains | Buy | $38.00 |
| 2026-03-03 | HC Wainwright & Co. | Maintains | Buy | $60.00 → $50.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 70 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 26.8% above the 50-day MA ($20.43).
- Price vs 200-day MA: Trading 37.1% above the 200-day MA ($18.89).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.06) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($25.90).
DYN Price Chart
Loading chart for DYN…
Fundamentals
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.